Hemoglobinopathies Treatment Market Report 2026

The hemoglobinopathies treatment market size has grown strongly in recent years. It will grow from $9.85 billion in 2025 to $10.79 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to improved survival rates in thalassemia patients, wider availability of blood transfusion services, expansion of specialized treatment centers, increased use of iron chelation therapy, growth in genetic disorder awareness.

The hemoglobinopathies treatment market size is expected to see strong growth in the next few years. It will grow to $14.79 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing approvals of gene editing therapies, rising investments in curative treatment research, expansion of personalized medicine adoption, growing access to advanced transplantation procedures, increasing focus on long-term disease management. Major trends in the forecast period include increasing adoption of gene therapy-based treatments, rising use of stem cell transplantation approaches, growing focus on personalized treatment protocols, expansion of advanced iron chelation therapies, enhanced integration of digital patient monitoring.

The growing impact of genetic inheritance is expected to drive the growth of the hemoglobinopathies treatment market in the coming years. Genetic inheritance refers to the transfer of characteristics from parents to offspring through DNA during sexual and asexual reproduction. Its importance has increased due to advancements in genetic research and technology, which have improved understanding of how genetic factors contribute to numerous diseases, including hemoglobinopathies. Genetic inheritance supports the growth of the hemoglobinopathies treatment market by enabling the development of targeted therapies, personalized medicine, drug development, and improved diagnostic approaches. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based charity supporting individuals with cystic fibrosis, reported that registered patients increased from approximately 11,148 in 2022 to 11,318 in 2023, reflecting a 1.5% year-over-year rise. Consequently, the increasing focus on genetic inheritance is propelling growth in the hemoglobinopathies treatment market.

Key companies in the hemoglobinopathies treatment market are advancing cell-based gene therapies to offer potentially curative solutions for patients with these genetic disorders. Cell-based gene therapies aim to correct underlying genetic defects, providing long-term or curative effects, reducing symptoms and complications, and expanding treatment options for affected individuals. For instance, in December 2023, Vertex Pharmaceuticals Incorporated, a U.S.-based biotech company, launched Casgevy for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia. Casgevy is a cell-based gene therapy that employs CRISPR/Cas9 technology to edit patients' hematopoietic stem cells, increasing fetal hemoglobin production to prevent red blood cell sickling. The therapy is a one-time procedure involving the collection, editing, and reinfusion of the patient’s stem cells.

In January 2025, IMMvention Therapeutix, a U.S.-based biotechnology company, entered into a strategic collaboration with Novo Nordisk to develop oral therapies for sickle cell disease and other chronic conditions. The collaboration aims to advance novel oral treatment options, improve patient outcomes, and accelerate innovation in therapies for chronic hematologic and metabolic disorders. IMMvention Therapeutix specializes in developing orally administered therapies for rare and chronic diseases.

Major companies operating in the hemoglobinopathies treatment market are Pfizer Inc., Sanofi S.A., Novartis AG, Bristol Myers Squibb, Vertex Pharmaceuticals Incorporated, Pharmacosmos A/S, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Gamida Cell Ltd., Beam Therapeutics, Intellia Therapeutics, Orchard Therapeutics plc, Editas Medicine, Agios Pharmaceuticals Inc., Emmaus Life Sciences Inc., Bluebird Bio Inc., CRISPR Therapeutics AG, Bioverativ Inc., Celgene Corporation.

North America was the largest region in the hemoglobinopathies treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemoglobinopathies treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemoglobinopathies treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hemoglobinopathies treatment market by increasing costs of imported biologics, gene therapy vectors, medical devices, laboratory equipment, and pharmaceutical raw materials used in advanced treatments. Treatment centers in North America and Europe are most affected due to dependence on imported specialty drugs and stem cell processing tools, while Asia-Pacific faces higher costs for advanced therapeutic manufacturing. These tariffs are increasing treatment expenses and impacting affordability in some regions. However, they are also driving domestic biopharmaceutical production, regional clinical research expansion, and local manufacturing of supportive treatment supplies.

The hemoglobinopathies treatment market research report is one of a series of new reports that provides hemoglobinopathies treatment market statistics, including hemoglobinopathies treatment industry global market size, regional shares, competitors with a hemoglobinopathies treatment market share, detailed hemoglobinopathies treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobinopathies treatment industry. This hemoglobinopathies treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hemoglobinopathies treatment refers to the management and care provided to individuals with hemoglobinopathies, which are genetic disorders characterized by abnormal or mutated hemoglobin molecules, such as sickle cell disease and thalassemia. The primary goal of treatment is to manage symptoms, prevent complications, and potentially offer curative options to improve patient outcomes and quality of life.

The main types of hemoglobinopathies treatment include stem cell therapy and blood transfusion. Stem cell therapy uses stem cells to treat or prevent disease and is applied in conditions such as thalassemia and sickle cell anemia. These treatments are distributed through various channels, including hospital pharmacies, online providers, and retail pharmacies.

The hemoglobinopathies treatment market consists of revenues earned by entities by providing services such as medication, blood transfusions, bone marrow transplantation, gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemoglobinopathies treatment market also includes sales of iron chelation therapy and hydroxyurea. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.